Home › Compare › DRNA vs STAG

DRNA vs STAG: Dividend Comparison 2026

DRNA yields 5.23% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DRNA wins by $9.9K in total portfolio value
10 years
DRNA
DRNA
● Live price
5.23%
Share price
$38.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.2K
Annual income
$731.12
Full DRNA calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — DRNA vs STAG

📍 DRNA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDRNASTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DRNA + STAG cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
DRNA pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DRNA
Annual income on $10K today (after 15% tax)
$444.79/yr
After 10yr DRIP, annual income (after tax)
$621.45/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, DRNA beats the other by $228.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DRNA + STAG for your $10,000?

DRNA: 50%STAG: 50%
100% STAG50/50100% DRNA
Portfolio after 10yr
$23.3K
Annual income
$596.67/yr
Blended yield
2.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on DRNA right now

DRNA
Analyst Ratings
11
Buy
6
Hold
Consensus: Buy
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DRNA buys
0
STAG buys
0
No recent congressional trades found for DRNA or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDRNASTAG
Forward yield5.23% ✓3.44%
Annual dividend / share$2.00 ✓$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3% ✓
Portfolio after 10y$28.2K ✓$18.3K
Annual income after 10y$731.12 ✓$462.22
Total dividends collected$6.3K ✓$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: DRNA vs STAG ($10,000, DRIP)

YearDRNA PortfolioDRNA Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$11,223$523.29$10,665$345.09+$558.00 → DRNA
2$12,558$548.88$11,364$357.70+$1.2K → DRNA
3$14,011$573.96$12,098$370.43+$1.9K → DRNA
4$15,590$598.48$12,869$383.28+$2.7K → DRNA
5$17,304$622.37$13,677$396.23+$3.6K → DRNA
6$19,161$645.59$14,524$409.27+$4.6K → DRNA
7$21,170$668.11$15,411$422.41+$5.8K → DRNA
8$23,342$689.88$16,339$435.61+$7.0K → DRNA
9$25,686$710.89$17,311$448.89+$8.4K → DRNA
10$28,216$731.12$18,327$462.22+$9.9K → DRNA

DRNA vs STAG: Complete Analysis 2026

DRNA — Stock

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

Full DRNA Calculator →

STAG — REIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this DRNA vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DRNA vs SCHDDRNA vs JEPIDRNA vs ODRNA vs KODRNA vs MAINDRNA vs PLDDRNA vs EQRDRNA vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.